close
Add to watchlist
Cleveland BioLabs Inc (CBLI)
Cleveland Biolabs, Inc. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and other acute stresses. The company's products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and intestine; Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation; and Curaxins, which include a first generation anticancer agent that demonstrated activity and safety in a Phase II clinical trial and an enhanced second generation compound that is entering formal pre-clinical development. Cleveland Biolabs has a strategic research partnership with Roswell Park Cancer Institute to develop its cancer and radioprotectant drug candidates; has a strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds, as well as to jointly manage the development and commercialization of compounds arising from selected projects; and has a collaborative relationship with the Armed Forces Radiobiology Research Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 3.12 |
| Volume | 479985 |
| Volume Avg | 143157 |
| 52 Week High | 8.70 |
| 52 Week Low | 2.10 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.33 |
| EPS change Q/Q | -61.22% |
| EPS change Q/Q Yr ago | -35.71% |
| EPS change Q/Q next Q est | -375% |
| EPS change Y/Y | -20.19% |
| REV change Q/Q | -34.21% |
| REV change Q/Q Yr ago | -40.48% |
| EPS next Q est | -0.04 |
| EPS next Y est | -0.46 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |